Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21
Khiron is the exclusive Latin American supplier to Project Twenty21 to create the largest body of evidence in Europe for the effectiveness and tolerability of medical cannabis
- First import of EU GMP medical cannabis products is complete
- Khiron branded products available to participating UK doctors, with first prescriptions now received
- Khiron has secured a strategic partnership with an EU GMP fulfilment partner which can deliver patient prescriptions to their homes
- UK medical cannabis clinics and doctors have received regulatory approval to conduct teleconsultations with patients, a new milestone in opening up patient access
- Approximately 1.4m people in Great Britain are using “street cannabis” to treat medically diagnosed, chronic health conditions (source: YouGov)
- By 2024, the UK medical cannabis market is predicted to be worth nearly £1bn, servicing nearly 340,000 active patients (source: Prohibition Partners)
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN), (OTCQX:KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced the receipt of its first medical cannabis prescriptions for patients participating in Project Twenty21 in the United Kingdom (UK). Khiron branded EU GMP medical cannabis is now available for prescription from doctors and clinics participating in Project Twenty21, Europe’s largest study of the effectiveness and tolerability of medical cannabis.
Khiron has been actively preparing to supply Project Twenty21 since first announcing its participation in November 2019. The supply of EU GMP medical cannabis is fully supported by the Company’s global medical education team, led by Dr. Maria Fernanda Arboleda, International Director for Medical Services. Khiron will leverage educational materials and key learnings from the Company’s Colombian cannabis experience in making therapeutic recommendations for Project Twenty21.
Leading the project, Professor David Nutt from the UK’s leading independent scientific body Drug Science commented: “Khiron’s assistance in delivering Project Twenty21 will expand the formulary significantly. Our shared vision, accelerating access of medical cannabis to patients who need it the most, will be greatly enhanced by the support provided by the Khiron team.”
Tejinder Virk, President of Khiron Europe, commented: “The receipt of our first prescriptions in the UK is a testament to Khiron’s regulatory strengths and globally diversified supply chain strategy. We have the flexibility to source medical cannabis products from multiple countries, with an aim to optimize for quality, speed and economics. The implementation of virtual consultations in the UK and mail order fulfilment are also huge milestones, which remove friction for patients and help to drive positive health outcomes.”
Khiron is the exclusive LatAm supplier to Project Twenty21, Europe’s first and largest national medical cannabis registry study in November 2019. Project Twenty21 aims to enrol 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis – with an aim to demonstrate to policymakers that medical cannabis should be as widely available, and affordable, as other approved medicines for patients who would benefit from them.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The Company delivers best in class regulatory compliance, has the first approved line of CBD cosmetic products on shelf in Colombia, and is fully authorized to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis in the country.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram @khironlife
Market and Industry Data
This press release includes market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, Khiron has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.